# BLRD Research Career Scientist Award Application

> **NIH VA IK6** · VA VETERANS ADMINISTRATION HOSPITAL · 2021 · —

## Abstract

Cancer is the second leading cause of death among veterans, and the Veterans Health Administration
estimates that there exist >170,000 cancer patients within in the VA system. Moreover, approximately 50,000
new cases of cancer are diagnosed each year. With the aging of the veteran population, this number is expected
to increase causing a concomitant encumbering of healthcare resources. Lung cancer, which is the leading
cause of death in both men and women in industrialized countries (an estimated 28% of all cancer deaths in the
USA), is also the leading cause of cancer death in the veteran population. Indeed, many veterans continue to
acquire tobacco addiction during their military service even though tobacco abuse is currently discouraged by
the military. Hence, there exists a very large percentage of high-risk current and former smokers cared for in the
VA health care system that would benefit from advances in therapeutic molecular targeting in the treatment of
lung cancer. Also, lung cancer is also linked to the well-established lung carcinogens, Agent Orange, Asbestos,
and Ionizing Radiation, which exposure to these agents are often are service-connected disorders.
 To address this issue, the research of the Chalfant Laboratory focuses on non-small cell lung cancer
(NSCLC), which represents the majority of lung cancers, carries a poor prognosis with a median survival of less
than 12 months, and has a cumulative five-year survival rate of approximately 15%. The research of the Chalfant
Laboratory is tailored to identify new cellular targets for the development of new treatments for this deadly
disease, which are thus, directly relevant to the patient care mission of the Department of Veterans Affairs.
Indeed, biomedical research investigating new strategies for the development of lung cancer therapeutics has
tremendous potential benefit to veterans, many of whom no longer smoke, yet remain at high risk for NSCLC.
 The Chalfant Laboratory focuses on two major, but diverse areas of basic science in regard to Cell
Biology, Microbiology, and Molecular Biology. Specifically, the Chalfant Laboratory studies mechanisms of cell
signaling associated with both bioactive lipids and RNA splicing with a focus on both basic science mechanisms
as well as in many cases clinical translation. In regard to RNA splicing research, the Chalfant Laboratory has
identified key RNA splicing events and signaling mechanisms mediating the tumor maintenance of NSCLC cells.
The applicant is further merging these finding with novel lipid signaling events linked to cell survival.
 The applicant, Dr. Chalfant, has been very productive with >100 peer-reviewed publications, and he has
been a distinguished member of the VA system for 17 years. His research work is supported by several NIH/VA
funded projects and currently, he has one VA Merit Review award and three NIH funded projects (2-R01 and 1-
U01). He has trained more than 40 trainees at very levels with a number of them cur...

## Key facts

- **NIH application ID:** 10614329
- **Project number:** 7IK6BX004603-04
- **Recipient organization:** VA VETERANS ADMINISTRATION HOSPITAL
- **Principal Investigator:** CHARLES E. CHALFANT
- **Activity code:** IK6 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2021
- **Award amount:** —
- **Award type:** 7
- **Project period:** 2019-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10614329

## Citation

> US National Institutes of Health, RePORTER application 10614329, BLRD Research Career Scientist Award Application (7IK6BX004603-04). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10614329. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*